INHIBITION OF PAF-INDUCED SYSTEMIC RESPONSES IN THE RAT, GUINEA-PIG, DOG AND PRIMATE BY THE RECEPTOR ANTAGONIST SRI 63-441

Abstract

Systemic administration of synthetic PAF produces a number of dose-dependent circulatory effects in a variety of species. We have evaluated a novel PAF antagonist, SRI 63-441, for its ability to inhibit PAF-induced effects in the rat, guinea pig, dog and primate. In the rat, a 100 ng kg-1 i.v. PAF challenge produced a (mean .+-. 1 S.D.) 39 .+-. 5% decrease in carotid blood pressure. Prior injection of SRI 63-441 inhibited this hypotensive response in a dose-dependent manner, with an ED50 of 0.15 mg/kg-1 i.v. In the guinea pig, PAF at 100 ng kg-1 elicited a 50 .+-. 8% increase in hematocrit and a 50 .+-. 11% elevation in bronchial resistance. The ED50 values for inhibition by SRI 63-441 of these two physiological parameters were 0.012 mg/kg-1 and 0.035 mg kg-1 i.a., respectively. Dogs challenged with 1.5 .mu.g/kg-1 PAF i.v. exhibited 28.7 .+-. 6.5% increase in hematocrit 10 min after injection. The ED50 value for SRI 63-441 inhibition of hemoconcentration in the dog was 0.18 mg kg-1 i.v. In the primate model of PAF-induced hemoconcentration, controls responded to 3.5 .mu.g kg-1 i.v. PAF with a 30 .+-. 6% increase in hematocrit. Using the primates in a cross-over design, the ED50 of SRI 63-441 was 0.11 mg kg-1 i.v. At this ED50 value, the ratio of nmol kg-1 PAF used versus nmol kg-1 antagonists is .apprx. 1:25. The effectiveness of SRI 63-441 in these models suggest potential clinical applications in disease states involving hyperpermeability and pulmonary dysfunction.